12:00 AM
Aug 05, 2013
 |  BC Week In Review  |  Company News  |  Deals

Acetylon, Array BioPharma, Celgene deal

Celgene paid $100 million up front in exchange for an exclusive option to acquire Acetylon. If Celgene exercises its option, Acetylon will receive at least $500 million in cash up front and Acetylon shareholders would be eligible for up to $250 million in regulatory...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >